What It Is

The emergence of targeted therapies over the last decade and a half has reshaped the treatment landscape for many cancers; with huge benefits to life expectancy and patient health as a result of a number of innovations. This “targeted revolution” is ongoing in many disease areas (Chronic Myeloid Leukaemia, Chromic Lymphocytic Leukaemia, Non-Small Cell Lung Cancer), whilst it is yet to occur in others (Pancreatic Cancer, Liver Cancer).

The industry requires a tool which has the capacity to meet tomorrow’s world, which must have the capability and flexibility to perform the tasks required of it, whilst maintaining accuracy, and a straight forward user approach.

The OncoStrat forecasting platform has the capability to address the needs of clients in the complex and evolving oncology landscape. It provides an overall market view (10 year forecast) segmented by:

  • Line of therapy
  • Regimens
  • Key products
  • Molecules

The platform is an easy to use interface, built on robust data sources and aligned with real-world clinical management algorithms. OncoStrat is supported by our proprietary Epiomic™ Patient Segmentation database, RxPriceIndex™ and Oncology Dosing Calculator™.

Outputs from the platform include:

  • Patients initiating treatment
  • Patient months of treatment
  • Patient share
  • Volume (mg/IU)
  • Revenue

The platform, in its Excel format, has been used and validated in over 14 major cancer sites across key global markets including the USA, France, Germany, Italy, Spain, UK, Japan, Brazil and China.  

The disease areas available include:

  • Renal cell carcinoma
  • Malignant melanoma
  • Prostate cancer
  • Breast cancer (HER2+ & Triple Negative)
  • Colorectal cancer
  • Ovarian cancer
  • Cervical cancer
  • Glioblastoma multiforme / astrocytoma
  • Non-small cell lung cancer
  • Hepatocellular carcinoma
  • Pancreatic cancer
  • Multiple myeloma
  • Non-Hodgkin’s Lymphomas & Leukaemias as follows:
    • Follicular lymphoma
    • Mantle cell lymphoma
    • Diffuse large B-cell lymphoma
    • Chronic lymphocytic leukaemia
    • Other aggressive NHL
    • Other indolent NHL
    • Chronic myeloid leukaemia
    • Acute lymphocytic leukaemia

Country Coverage includes UK, USA, France, Germany, Italy, Spain, Brazil & Japan.